Dearborn Partners
XBI icon

Dearborn Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Dearborn Partners’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$206K Buy
+1,305
New +$206K 0.01% 270
2024
Q4 		– Sell
-2,705
Closed -$267K – 276
2024
Q3 		$267K Buy
2,705
+265
+11% +$26K 0.01% 242
2024
Q2 		$226K Buy
+2,440
New +$219K 0.01% 245

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $64.4B AUM 36.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Dearborn Partners's XBI Position: Q3 2026 in Review

Dearborn Partners opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2026: 1,305 shares worth $206K. The stake represents 0.01% of the portfolio and ranks #270 among its holdings. This is a return to the name: Dearborn Partners previously reported a position in XBI as recently as Q3 2024.

Dearborn Partners first reported a position in XBI in Q2 2024 and has held it in 3 quarters since. The position peaked at $267K in Q3 2024. 820 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Dearborn Partners held 1,305 shares of State Street SPDR S&P Biotech ETF worth $206K as of Q3 2026.
  • State Street SPDR S&P Biotech ETF was a new Dearborn Partners position in Q3 2026.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Dearborn Partners's portfolio in Q3 2026, its #270 holding.
  • Dearborn Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2024 and has held it in 3 quarters since.
  • Dearborn Partners's State Street SPDR S&P Biotech ETF position peaked at $267K in Q3 2024.
  • 820 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Dearborn Partners's 13F filing for Q3 2026, filed 13 Nov 2026.